MentionFox
Home › 5%+ stakes › Manufacturing (industry group 28), latest filing in April 2026
5%+ stakes

Manufacturing (industry group 28), latest filing in April 2026

24 companies with 5%+ holders, every filing linked: Abbott Laboratories, AbbVie Inc, Arq, Inc., ASP Isotopes Inc., AstraZeneca PLC, Avient Corp and more. Each section is the company's full record from its filings, newest filings first within each section.

On this page

Abbott Laboratories

At 5% or more1
Filings3
Latest filing2026-04-29

Abbott Laboratories has 3 Schedule 13D or 13G filings on record since 2025-12-03. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.5%130,676,776SCHEDULE 13G, 2026-04-292026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management17,726,8430130,676,7760SCHEDULE 13G, 2026-04-29
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Abbott Laboratories by CUSIP 002824100 and gives its principal executive office as 100 Abbott Park Road, Abbott Park, IL 60064 (SCHEDULE 13G, 2026-04-29).

FiledHolderPercentFiling
2025-12-03The Vanguard Group10.05%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management7.5%SCHEDULE 13G
DateRecordFigureOur pageSource
April 27, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

AbbVie Inc

At 5% or more1
Filings3
Latest filing2026-04-29

AbbVie Inc has 3 Schedule 13D or 13G filings on record since 2025-07-07. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.51%132,924,058SCHEDULE 13G, 2026-04-292026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management18,043,7340132,924,0580SCHEDULE 13G, 2026-04-29
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies AbbVie Inc by CUSIP 00287Y109 and gives its principal executive office as 1 North Waukegan Road, North Chicago, IL 60064 (SCHEDULE 13G, 2026-04-29).

FiledHolderPercentFiling
2025-07-07The Vanguard Group10.03%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management7.51%SCHEDULE 13G

Arq, Inc.

At 5% or more1
Filings3
Latest filing2026-04-27

Arq, Inc. has 3 Schedule 13D or 13G filings on record since 2026-01-28. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Daniel Kaufman5.12%2,191,278SCHEDULE 13G, 2026-03-122026-03-11
Orin Hirschman0%0SCHEDULE 13G/A, 2026-04-272026-03-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Daniel Kaufman2,191,27802,191,2780SCHEDULE 13G, 2026-03-12
Orin Hirschman0000SCHEDULE 13G/A, 2026-04-27
AIGH Capital Management LLC0000SCHEDULE 13G/A, 2026-04-27

The latest filing identifies Arq, Inc. by CUSIP 00770C101 and gives its principal executive office as 8051 E. Maplewood Ave., Suite 210, Greenwood Village, CO 80111 (SCHEDULE 13G/A, 2026-04-27).

FiledHolderPercentFiling
2026-01-28Orin Hirschman5.8%SCHEDULE 13G/A
2026-03-12Daniel Kaufman5.12%SCHEDULE 13G
2026-04-27Orin Hirschman0%SCHEDULE 13G/A
DateRecordFigureOur pageSource
August 28, 2026Leadership change: Peter Owino appointed, Chief Accounting Officer—Leadership changesSource
July 23, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource
June 18, 2026Leadership change: Peter Owino appointed, Chief Accounting Officer, and 1 more—Leadership changesSource
May 27, 2026Leadership change: Shimon Steinmetz appointed, Chief Financial Officer, and 1 more—Leadership changesSource
May 1, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

ASP Isotopes Inc.

At 5% or more4
Filings9
Latest filing2026-04-27

ASP Isotopes Inc. has 9 Schedule 13D or 13G filings on record since 2025-08-14. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Mann Paul Elliot7%7,759,538SCHEDULE 13G/A, 2026-02-172025-12-31
BlackRock, Inc.6.6%8,274,763SCHEDULE 13G/A, 2026-04-272026-03-31
AK Jensen Investment Management Ltd5.4%4,955,261SCHEDULE 13G/A, 2025-11-142025-09-30
Encompass Capital Advisors LLC5.13%6,413,362SCHEDULE 13G, 2026-01-232026-01-16
AWM Investment Company, Inc.4.3%3,931,186SCHEDULE 13G/A, 2025-08-142025-06-30
BNP Paribas Asset Management UK Ltd0.9%944,326SCHEDULE 13G/A, 2026-02-092025-12-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Mann Paul Elliot7,759,53807,759,5380SCHEDULE 13G/A, 2026-02-17
BlackRock, Inc.8,117,27708,274,7630SCHEDULE 13G/A, 2026-04-27
BNP Paribas Asset Management UK Ltd944,3260944,3260SCHEDULE 13G/A, 2026-02-09
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies ASP Isotopes Inc. by CUSIP 00218A105 and gives its principal executive office as 2200 Ross Avenue, Suite 4575E, Dallas, TX 75201 (SCHEDULE 13G/A, 2026-04-27).

FiledHolderPercentFiling
2025-08-14AWM Investment Company, Inc.6.9%SCHEDULE 13G
2025-08-14AWM Investment Company, Inc.4.3%SCHEDULE 13G/A
2025-11-14AK Jensen Investment Management Ltd5.4%SCHEDULE 13G/A
2026-01-23Encompass Capital Advisors LLC5.13%SCHEDULE 13G
2026-01-30The Vanguard Group5.77%SCHEDULE 13G
2026-02-09BNP Paribas Asset Management UK Ltd0.9%SCHEDULE 13G/A
2026-02-17Mann Paul Elliot7%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-27BlackRock, Inc.6.6%SCHEDULE 13G/A

AstraZeneca PLC

At 5% or more1
Filings1
Latest filing2026-04-28

AstraZeneca PLC has 1 Schedule 13D or 13G filing on record since 2026-04-28. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management5.02%77,965,099SCHEDULE 13G, 2026-04-282026-03-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management32,924,957077,965,0990SCHEDULE 13G, 2026-04-28

The latest filing identifies AstraZeneca PLC by CUSIP G0593M107 and gives its principal executive office as 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge (SCHEDULE 13G, 2026-04-28).

FiledHolderPercentFiling
2026-04-28Vanguard Capital Management5.02%SCHEDULE 13G

Avient Corp

At 5% or more3
Filings5
Latest filing2026-04-29

Avient Corp has 5 Schedule 13D or 13G filings on record since 2025-07-15. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Portfolio Management6.04%5,539,975SCHEDULE 13G, 2026-04-282026-03-31
Vanguard Capital Management5.24%4,812,578SCHEDULE 13G, 2026-04-292026-03-31
Dimensional Fund Advisors LP5.1%4,690,922SCHEDULE 13G, 2025-07-152025-06-30
Franklin Mutual Advisers, LLC4.9%4,554,936SCHEDULE 13G/A, 2025-08-052025-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Portfolio Management37,36205,539,9750SCHEDULE 13G, 2026-04-28
Vanguard Capital Management696,56504,812,5780SCHEDULE 13G, 2026-04-29
Franklin Mutual Advisers, LLC4,346,68704,554,9360SCHEDULE 13G/A, 2025-08-05
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Avient Corp by CUSIP 05368V106 and gives its principal executive office as 33587 Walker Road, Avon Lake, OH 44012 (SCHEDULE 13G, 2026-04-29).

FiledHolderPercentFiling
2025-07-15Dimensional Fund Advisors LP5.1%SCHEDULE 13G
2025-08-05Franklin Mutual Advisers, LLC4.9%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-28Vanguard Portfolio Management6.04%SCHEDULE 13G
2026-04-29Vanguard Capital Management5.24%SCHEDULE 13G
DateRecordFigureOur pageSource
October 9, 2026Leadership change: Michael J. Frank appointed, President and Chief Executive Officer—Leadership changesSource
April 27, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

Balchem Corp

At 5% or more3
Filings4
Latest filing2026-04-29

Balchem Corp has 4 Schedule 13D or 13G filings on record since 2025-07-18. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.14.4%4,688,457SCHEDULE 13G/A, 2025-07-182025-06-30
Vanguard Portfolio Management6.93%2,221,969SCHEDULE 13G, 2026-04-282026-03-31
Vanguard Capital Management5.24%1,680,971SCHEDULE 13G, 2026-04-292026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.4,625,78304,688,4570SCHEDULE 13G/A, 2025-07-18
Vanguard Portfolio Management28,55202,221,9690SCHEDULE 13G, 2026-04-28
Vanguard Capital Management248,88301,680,9710SCHEDULE 13G, 2026-04-29
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Balchem Corp by CUSIP 057665200 and gives its principal executive office as 5 Paragon Dr, Montvale, NJ 07645 (SCHEDULE 13G, 2026-04-29).

FiledHolderPercentFiling
2025-07-18BlackRock, Inc.14.4%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-28Vanguard Portfolio Management6.93%SCHEDULE 13G
2026-04-29Vanguard Capital Management5.24%SCHEDULE 13G

Chemours Co

At 5% or more4
Filings8
Latest filing2026-04-29

Chemours Co has 8 Schedule 13D or 13G filings on record since 2025-07-17. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.14.3%21,484,477SCHEDULE 13G/A, 2026-04-242026-03-31
Vanguard Portfolio Management6.96%10,456,302SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Capital Management5.26%7,903,519SCHEDULE 13G, 2026-04-292026-03-31
Millennium Management LLC5.1%7,576,095SCHEDULE 13G/A, 2025-08-082025-06-30
Fmr LLC3.4%5,101,254SCHEDULE 13G/A, 2025-08-062025-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.21,244,817021,484,4770SCHEDULE 13G/A, 2026-04-24
Vanguard Portfolio Management130,961010,456,3020SCHEDULE 13G, 2026-04-29
Vanguard Capital Management1,129,60207,903,5190SCHEDULE 13G, 2026-04-29
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Chemours Co by CUSIP 163851108 and gives its principal executive office as 1007 Market Street, Wilmington, DE 19898 (SCHEDULE 13G, 2026-04-29).

FiledHolderPercentFiling
2025-07-17BlackRock, Inc.16.9%SCHEDULE 13G/A
2025-07-29The Vanguard Group11.8%SCHEDULE 13G/A
2025-08-06Fmr LLC3.4%SCHEDULE 13G/A
2025-08-08Millennium Management LLC5.1%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-24BlackRock, Inc.14.3%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management5.26%SCHEDULE 13G
2026-04-29Vanguard Portfolio Management6.96%SCHEDULE 13G

Church & Dwight Co Inc

At 5% or more2
Filings3
Latest filing2026-04-29

Church & Dwight Co Inc has 3 Schedule 13D or 13G filings on record since 2026-03-26. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.5%17,779,914SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Portfolio Management5.47%12,974,089SCHEDULE 13G, 2026-04-292026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management2,367,137017,779,9140SCHEDULE 13G, 2026-04-29
Vanguard Portfolio Management34,467012,974,0890SCHEDULE 13G, 2026-04-29
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Church & Dwight Co Inc by CUSIP 171340102 and gives its principal executive office as 500 Charles Ewing Blvd, Princeton South Corporate Cent, Ewing, NJ 08628 (SCHEDULE 13G, 2026-04-29).

FiledHolderPercentFiling
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management7.5%SCHEDULE 13G
2026-04-29Vanguard Portfolio Management5.47%SCHEDULE 13G
DateRecordFigureOur pageSource
October 29, 2026Leadership change: Jonathon J. Nudi appointed, Director—Leadership changesSource

Colgate-Palmolive Co

At 5% or more1
Filings2
Latest filing2026-04-29

Colgate-Palmolive Co has 2 Schedule 13D or 13G filings on record since 2026-03-26. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: 2 filings or notices, latest 2026-05-01 (layoff filings and notices).

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.52%60,404,276SCHEDULE 13G, 2026-04-292026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management8,184,452060,404,2760SCHEDULE 13G, 2026-04-29
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Colgate-Palmolive Co by CUSIP 194162103 and gives its principal executive office as 300 Park Avenue, 11th Floor, New York, NY 10022 (SCHEDULE 13G, 2026-04-29).

FiledHolderPercentFiling
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management7.52%SCHEDULE 13G
DateRecordFigureOur pageSource
April 9, 2026Leadership change: Betsy Fishbone appointed, Chief Legal Officer, and 1 more—Leadership changesSource

Eastman Chemical Co

At 5% or more3
Filings7
Latest filing2026-04-29

Eastman Chemical Co has 7 Schedule 13D or 13G filings on record since 2025-08-05. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.13.8%15,745,661SCHEDULE 13G/A, 2026-04-242026-03-31
Vanguard Portfolio Management6.7%7,670,415SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Capital Management5.22%5,974,518SCHEDULE 13G, 2026-04-292026-03-31
Franklin Resources, Inc.3.9%4,493,013SCHEDULE 13G/A, 2025-08-052025-06-30
Capital Research Global Investors3.7%4,246,293SCHEDULE 13G/A, 2025-08-132025-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.15,437,852015,745,6610SCHEDULE 13G/A, 2026-04-24
Vanguard Portfolio Management42,06107,670,4150SCHEDULE 13G, 2026-04-29
Vanguard Capital Management865,80005,974,5180SCHEDULE 13G, 2026-04-29
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Eastman Chemical Co by CUSIP 277432100 and gives its principal executive office as 200 South Wilcox Drive, Kingsport, TN 37660 (SCHEDULE 13G, 2026-04-29).

FiledHolderPercentFiling
2025-08-05Franklin Resources, Inc.3.9%SCHEDULE 13G/A
2025-08-13Capital Research Global Investors3.7%SCHEDULE 13G/A
2025-12-04BlackRock, Inc.11.9%SCHEDULE 13G/A
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-24BlackRock, Inc.13.8%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management5.22%SCHEDULE 13G
2026-04-29Vanguard Portfolio Management6.7%SCHEDULE 13G

Gilead Sciences Inc

At 5% or more2
Filings3
Latest filing2026-04-29

Gilead Sciences Inc has 3 Schedule 13D or 13G filings on record since 2026-02-05. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.51%93,327,127SCHEDULE 13G, 2026-04-292026-03-31
Fmr LLC5.3%65,539,477SCHEDULE 13G, 2026-02-052025-12-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-262026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management12,672,351093,327,1270SCHEDULE 13G, 2026-04-29
Fmr LLC57,299,411065,539,4770SCHEDULE 13G, 2026-02-05
Abigail P. Johnson0065,539,4770SCHEDULE 13G, 2026-02-05
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-26

The latest filing identifies Gilead Sciences Inc by CUSIP 375558103 and gives its principal executive office as 333 Lakeside Drive, Foster City, CA 94404 (SCHEDULE 13G, 2026-04-29).

FiledHolderPercentFiling
2026-02-05Fmr LLC5.3%SCHEDULE 13G
2026-03-26The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Capital Management7.51%SCHEDULE 13G

Halozyme Therapeutics Inc

At 5% or more2
Filings3
Latest filing2026-04-30

Halozyme Therapeutics Inc has 3 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.10.2%12,612,300SCHEDULE 13G/A, 2025-07-172025-06-30
Vanguard Capital Management5.21%6,173,547SCHEDULE 13G, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.12,211,841012,612,3000SCHEDULE 13G/A, 2025-07-17
Vanguard Capital Management902,32906,173,5470SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Halozyme Therapeutics Inc by CUSIP 40637H109 and gives its principal executive office as 12390 El Camino Real, San Diego, CA 92130 (SCHEDULE 13G, 2026-04-30).

FiledHolderPercentFiling
2025-07-17BlackRock, Inc.10.2%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management5.21%SCHEDULE 13G
DateRecordFigureOur pageSource
September 30, 2026Leadership change: James Daly appointed—Leadership changesSource
August 18, 2026Leadership change: Dannielle Appelhans appointed—Leadership changesSource
July 2, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource
April 30, 2026Leadership change: Darren Snellgrove appointed, Chief Financial Officer—Leadership changesSource

IDEXX Laboratories Inc

At 5% or more2
Filings3
Latest filing2026-10-30

IDEXX Laboratories Inc has 3 Schedule 13D or 13G filings on record since 2026-03-27. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.51%5,976,472SCHEDULE 13G, 2026-04-302026-03-31
Vanguard Portfolio Management5.04%3,974,472SCHEDULE 13G, 2026-10-302026-09-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management793,96505,976,4720SCHEDULE 13G, 2026-04-30
Vanguard Portfolio Management18,54503,974,4720SCHEDULE 13G, 2026-10-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies IDEXX Laboratories Inc by CUSIP 45168D104 and gives its principal executive office as One Idexx Drive, Westbrook, ME 04092 (SCHEDULE 13G, 2026-10-30).

FiledHolderPercentFiling
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management7.51%SCHEDULE 13G
2026-10-30Vanguard Portfolio Management5.04%SCHEDULE 13G

International Flavors & Fragrances Inc

At 5% or more2
Filings3
Latest filing2026-04-30

International Flavors & Fragrances Inc has 3 Schedule 13D or 13G filings on record since 2025-08-13. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Dodge & Cox13.7%35,047,387SCHEDULE 13G/A, 2025-08-132025-06-30
Vanguard Capital Management7.37%18,842,232SCHEDULE 13G, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Dodge & Cox33,346,737035,047,3870SCHEDULE 13G/A, 2025-08-13
Vanguard Capital Management2,604,007018,842,2320SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies International Flavors & Fragrances Inc by CUSIP 459506101 and gives its principal executive office as 521 West 57th Street, New York, NY 10019 (SCHEDULE 13G, 2026-04-30).

FiledHolderPercentFiling
2025-08-13Dodge & Cox13.7%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management7.37%SCHEDULE 13G
DateRecordFigureOur pageSource
November 3, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

Linde PLC

At 5% or more1
Filings2
Latest filing2026-04-30

Linde PLC has 2 Schedule 13D or 13G filings on record since 2026-03-27. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.52%34,874,653SCHEDULE 13G, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management4,641,583034,874,6530SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Linde PLC by CUSIP G54950103 and gives its principal executive office as 10 Riverview Dr, Danbury, CT 06810 (SCHEDULE 13G, 2026-04-30).

FiledHolderPercentFiling
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management7.52%SCHEDULE 13G

Merck & Co Inc

At 5% or more1
Filings2
Latest filing2026-04-30

Merck & Co Inc has 2 Schedule 13D or 13G filings on record since 2026-03-27. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.53%186,323,766SCHEDULE 13G, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management25,336,1420186,323,7660SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Merck & Co Inc by CUSIP 58933Y105 and gives its principal executive office as 126 East Lincoln Avenue, PO Box 2000, Rahway, NJ 07065 (SCHEDULE 13G, 2026-04-30).

FiledHolderPercentFiling
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management7.53%SCHEDULE 13G
DateRecordFigureOur pageSource
October 13, 2026Leadership change: Paul J. Diaz appointed—Leadership changesSource

MindWalk Holdings Corp.

At 5% or more1
Filings1
Latest filing2026-04-23

MindWalk Holdings Corp. has 1 Schedule 13D or 13G filing on record since 2026-04-23. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Ingalls & Snyder LLC5.8%2,729,122SCHEDULE 13G/A, 2026-04-232025-12-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Ingalls & Snyder LLC0002,729,122SCHEDULE 13G/A, 2026-04-23

The latest filing identifies MindWalk Holdings Corp. by CUSIP 602687105 and gives its principal executive office as 3204-4464 MARKHAM STREET, VICTORIA (SCHEDULE 13G/A, 2026-04-23).

FiledHolderPercentFiling
2026-04-23Ingalls & Snyder LLC5.8%SCHEDULE 13G/A

Procter & Gamble Co

At 5% or more1
Filings3
Latest filing2026-04-30

Procter & Gamble Co has 3 Schedule 13D or 13G filings on record since 2025-09-08. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.52%174,810,071SCHEDULE 13G, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management23,760,1690174,810,0710SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Procter & Gamble Co by CUSIP 742718109 and gives its principal executive office as 1 Procter and Gamble Plaza, Cincinnati, OH 45202 (SCHEDULE 13G, 2026-04-30).

FiledHolderPercentFiling
2025-09-08The Vanguard Group10.04%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management7.52%SCHEDULE 13G

Regeneron Pharmaceuticals Inc

At 5% or more1
Filings3
Latest filing2026-04-30

Regeneron Pharmaceuticals Inc has 3 Schedule 13D or 13G filings on record since 2025-08-06. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Vanguard Capital Management7.37%7,660,810SCHEDULE 13G, 2026-04-302026-03-31
Fmr LLC3.2%3,359,563SCHEDULE 13G/A, 2025-08-062025-06-30
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Vanguard Capital Management1,005,89707,660,8100SCHEDULE 13G, 2026-04-30
Fmr LLC3,156,85803,359,5630SCHEDULE 13G/A, 2025-08-06
Abigail P. Johnson003,359,5630SCHEDULE 13G/A, 2025-08-06
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Regeneron Pharmaceuticals Inc by CUSIP 75886F107 and gives its principal executive office as 777 Old Saw Mill River Road, Tarrytown, NY 10591 (SCHEDULE 13G, 2026-04-30).

FiledHolderPercentFiling
2025-08-06Fmr LLC3.2%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management7.37%SCHEDULE 13G
DateRecordFigureOur pageSource
September 30, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

Sealed Air Corp

At 5% or more3
Filings10
Latest filing2026-04-30

Sealed Air Corp has 10 Schedule 13D or 13G filings on record since 2025-11-07. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.11.2%16,577,118SCHEDULE 13G/A, 2026-04-292026-03-31
Vanguard Portfolio Management5.77%8,509,902SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Capital Management5.24%7,734,256SCHEDULE 13G, 2026-04-302026-03-31
Integrated Core Strategies (US) LLC3.7%5,374,505SCHEDULE 13G/A, 2025-11-182025-11-11
BlackRock Portfolio Management LLC0.1%125,194SCHEDULE 13G/A, 2026-04-292026-03-31
T. Rowe Price Investment Management, Inc.0%140SCHEDULE 13G/A, 2026-02-172025-12-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.16,294,932016,577,1180SCHEDULE 13G/A, 2026-04-29
Vanguard Portfolio Management17,65008,509,9020SCHEDULE 13G, 2026-04-29
Vanguard Capital Management1,122,55707,734,2560SCHEDULE 13G, 2026-04-30
BlackRock Portfolio Management LLC77,4520125,1940SCHEDULE 13G/A, 2026-04-29

The latest filing identifies Sealed Air Corp by CUSIP 81211K100 and gives its principal executive office as 2415 Cascade Pointe Blvd, Charlotte, NC 28208 (SCHEDULE 13G, 2026-04-30).

FiledHolderPercentFiling
2025-11-07Integrated Core Strategies (US) LLC5.1%SCHEDULE 13G
2025-11-14T. Rowe Price Investment Management, Inc.5.7%SCHEDULE 13G/A
2025-11-18Integrated Core Strategies (US) LLC3.7%SCHEDULE 13G/A
2026-01-30The Vanguard Group10.88%SCHEDULE 13G/A
2026-02-17T. Rowe Price Investment Management, Inc.0%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29BlackRock, Inc.11.2%SCHEDULE 13G/A
2026-04-29BlackRock Portfolio Management LLC0.1%SCHEDULE 13G/A
2026-04-29Vanguard Portfolio Management5.77%SCHEDULE 13G
2026-04-30Vanguard Capital Management5.24%SCHEDULE 13G
DateRecordFigureOur pageSource
April 9, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource

Turn Therapeutics Inc.

At 5% or more1
Filings1
Latest filing2026-04-06

Turn Therapeutics Inc. has 1 Schedule 13D or 13G filing on record since 2026-04-06. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Bradley Burnam52.76%15,716,260SCHEDULE 13G, 2026-04-062025-12-31
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Bradley Burnam15,716,260015,716,2600SCHEDULE 13G, 2026-04-06

The latest filing identifies Turn Therapeutics Inc. by CUSIP 90021W105 and gives its principal executive office as 250 NORTH WESTLAKE BLVD., # 210, WESTLAKE VILLAGE, CA 91362 (SCHEDULE 13G, 2026-04-06).

FiledHolderPercentFiling
2026-04-06Bradley Burnam52.76%SCHEDULE 13G
DateRecordFigureOur pageSource
August 26, 2026Form D, private offering$1.65M soldForm D pageSource
May 13, 2026Crowdfunding filing, Form C-TR—CrowdfundingSource
April 29, 2025Crowdfunding filing, Form C-AR—CrowdfundingSource
March 25, 2025Crowdfunding filing, Form C-U$15K targetCrowdfundingSource
January 17, 2025Crowdfunding filing, Form C/A$15K targetCrowdfundingSource
December 18, 2024Crowdfunding filing, Form C/A$15K targetCrowdfundingSource
November 12, 2024Crowdfunding filing, Form C-U$15K targetCrowdfundingSource
October 22, 2024Crowdfunding filing, Form C$15K targetCrowdfundingSource
August 19, 2024Crowdfunding filing, Form C/A$15K targetCrowdfundingSource
July 15, 2024Crowdfunding filing, Form C/A$15K targetCrowdfundingSource

Viking Therapeutics Inc

At 5% or more2
Filings4
Latest filing2026-04-30

Viking Therapeutics Inc has 4 Schedule 13D or 13G filings on record since 2025-08-06. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
Fmr LLC5.1%5,772,051SCHEDULE 13G/A, 2025-11-052025-09-30
Vanguard Capital Management5.08%5,877,263SCHEDULE 13G, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
Fmr LLC5,724,56105,772,0510SCHEDULE 13G/A, 2025-11-05
Abigail P. Johnson005,772,0510SCHEDULE 13G/A, 2025-11-05
Vanguard Capital Management864,76105,877,2630SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies Viking Therapeutics Inc by CUSIP 92686J106 and gives its principal executive office as 9920 Pacific Heights Blvd, Suite 350, San Diego, CA 92121 (SCHEDULE 13G, 2026-04-30).

FiledHolderPercentFiling
2025-08-06Fmr LLC8.7%SCHEDULE 13G/A
2025-11-05Fmr LLC5.1%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-30Vanguard Capital Management5.08%SCHEDULE 13G

WD-40 Co

At 5% or more3
Filings4
Latest filing2026-04-30

WD-40 Co has 4 Schedule 13D or 13G filings on record since 2025-10-17. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

HolderPercentSharesLatestEvent date
BlackRock, Inc.14.3%1,930,742SCHEDULE 13G/A, 2025-10-172025-09-30
Vanguard Portfolio Management7.78%1,049,971SCHEDULE 13G, 2026-04-292026-03-31
Vanguard Capital Management5.26%709,470SCHEDULE 13G, 2026-04-302026-03-31
The Vanguard Group0%0SCHEDULE 13G/A, 2026-03-272026-03-13
Reporting personSole votingShared votingSole dispositiveShared dispositiveFiling
BlackRock, Inc.1,904,71301,930,7420SCHEDULE 13G/A, 2025-10-17
Vanguard Portfolio Management11,83201,049,9710SCHEDULE 13G, 2026-04-29
Vanguard Capital Management103,8160709,4700SCHEDULE 13G, 2026-04-30
The Vanguard Group0000SCHEDULE 13G/A, 2026-03-27

The latest filing identifies WD-40 Co by CUSIP 929236107 and gives its principal executive office as 1061 Cudahy Place, San Diego, CA 92110 (SCHEDULE 13G, 2026-04-30).

FiledHolderPercentFiling
2025-10-17BlackRock, Inc.14.3%SCHEDULE 13G/A
2026-03-27The Vanguard Group0%SCHEDULE 13G/A
2026-04-29Vanguard Portfolio Management7.78%SCHEDULE 13G
2026-04-30Vanguard Capital Management5.26%SCHEDULE 13G
DateRecordFigureOur pageSource
September 3, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource
June 25, 2026Leadership change filing (Form 8-K, Item 5.02)—Leadership changesSource
June 4, 2026Leadership change: Sara K. Hyzer departs, Chief Financial Officer—Leadership changesSource

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All 5%+ stakes

RSS